Entity Addresses, Address Type [Axis]
Business Contact [Member]
Class of Stock [Axis]
American Depositary Shares [Member]
Ordinary Shares Par Value 0. 0001 Per Share [Member]
Equity Components [Axis]
Corporate Capital [Member]
Additional Paid-in Capital [Member]
Common Stock [Member]
Retained Earnings [Member]
Sale of Stock [Axis]
IPO [Member]
Over-Allotment Option [Member]
Plan Name [Axis]
Equity Incentive Plan 2021 - 2025 [Member]
Statistical Measurement [Axis]
Maximum [Member]
Long-Lived Tangible Asset [Axis]
Equipment And Furniture [Member]
Electronic Office Equipment [Member]
Leasehold Improvements [Member]
Income Tax Authority [Axis]
No Expiration Date [Member]
No Expiration Date - DL 98/2011 [Member]
Related Party Transaction [Axis]
Research And Development Expense Related Party [Member]
Investment, Name [Axis]
Quota A [Member]
Quota B [Member]
Quota C [Member]
Quota D [Member]
Quota E [Member]
Equity Method Investment, Nonconsolidated Investee [Axis]
Minimum [Member]
Award Type [Axis]
Share-based Payment Arrangement, Option [Member]
Income Statement Location [Axis]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Third Parties [Member]
Product and Service [Axis]
Consultants and Other Third Parties [Member]
Related Parties [Member]
Materials And Supplies [Member]
Compensation [Member]
Travel And Entertainment [Member]
Other [Member]
San Raffle Hospital [Member]
Spafid SPA [Member]
Fidim Srl [Member]
Title of Individual [Axis]
Pierluigi Paracchi [Member]
Director [Member]
Related Party [Axis]
Naldini [Member]
Gentner [Member]
XDG Biomed LLC [Member]
Richard Slansky [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
License Agreement Amendment One [Member]
Scenario [Axis]
First Indication [Member]
Second Indication [Member]
Third Indication [Member]
License Agreement Amendment Two [Member]
San Raffaele Hospital [Member]
License Agreement Amendment Three [Member]
First Solid Cancer Indication [Member]
Second Solid Cancer Indication [Member]
License Agreement Amendment Five [Member]
First Solid Cancer Indication Option Fee [Member]
Second Solid Cancer Indication Option Fee [Member]
Research Funding Agreement [Member]
Sponsor Research Agreement [Member]
Accounting Legal and Other Professional [Member]
Communication and IT Related [Member]
Facility and Insurance Related [Member]
OSR-SanRaffaeleHospital [Member]
OSR Operating Leases And Office Rent [Member]
AGC Manufacturing [Member]
LVV Batch [Member]
Plasmid Batch [Member]
Lympho hematopoietic [Member]
Solid Cancer [Member]
Related Milestone One [Member]
Related Milestone Two [Member]
Legal Entity [Axis]
OSR [Member]
AGC Biologics Agreement [Member]
AGC Agreement [Member]
Amendment Four [Member]
Amendment Five [Member]
Amendment Six [Member]
Amendment Seven [Member]
GMP Batch [Member]
Service Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Roth Capital [Member]
Entity Addresses [Table]
Entity Addresses [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Contact Personnel Name
Contact Personnel Email Address
ICFR Auditor Attestation Flag
Auditor Firm ID
Auditor Name
Auditor Location
Income Statement [Abstract]
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Awards and Subsidies
Other income
Finance expense
Total other income (expense), net
Loss before income taxes
Income taxes benefit (expenses)
Net loss
Net loss and comprehensive loss
Loss per share information:
Net loss
Net loss per share - basic and diluted
Weighted average number of shares outstanding - basic and diluted
Statement of Financial Position [Abstract]
Assets
Current assets
Cash and cash equivalents
Prepaid expenses and other current assets
Prepaid expenses and other current assets - related party
Total current assets
Non-current assets
Property and equipment, net
Other non-current assets - related party
Other non-current assets
Total non-current assets
Total assets
Liabilities and quotaholders’ and stockholders’ equity
Current liabilities
Accounts payable
Accounts payable - related party
Accrued expenses
Accrued expenses - related party
Other current liabilities
Total current liabilities
Non-current liabilities
Retirement benefit obligation
Total long-term liabilities
Commitments and contingencies (Note 13)
Quotaholders’ and stockholders’ equity
Corporate capital
Additional paid-in capital
Common stock, no par value, 59,700,000 shares authorized and 18,216,858 shares issued and outstanding
Accumulated deficit
Total quotaholders’ and stockholders’ equity
Total liabilities and quotaholders’ and stockholders’ equity
Common stock, par value
Common Stock, shares authorized
Common Stock, shares issued
Common Stock, shares outstanding
Statement [Table]
Statement [Line Items]
Balance
Shares, Outstanding, Beginning Balance
Capital increase, net of issuance costs
Share -based compensation
Capital increase from exercise of options on Quota B
Quota B repurchased
Corporate capital adjustment from Srl to SpA
Corporate capital adjustment from Srl to SPA share
Capital increase related to SpA
Capital increase related to SPA share
Conversion adjustment from Srl to SpA
Capital increase from IPO, net of issuance costs
Capital increase from IPO net issuance costs share
Balance
Shares, Outstanding, Ending Balance
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Retirement benefit obligation
Share-based compensation
Changes in operating assets and liabilities
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accounts payable - related party
Accrued expenses
Accrued expenses - related party
Other current liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Net proceeds from IPO
Proceeds from the exercise of stock options
Proceeds from capital increase
Issuance costs
Prepaid offering costs
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES
Non-cash financing activities: accrued IPO offering costs
Non-cash financing activities: deferred offering costs accrued at year end
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and history
Accounting Policies [Abstract]
Summary of significant accounting policies
Research and Development [Abstract]
Research and development
General And Administrative
General and administrative
Income Tax Disclosure [Abstract]
Income taxes
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other current assets
Property, Plant and Equipment [Abstract]
Property and equipment, net
Other Non-current Assets
Other non-current assets
Retirement Benefits [Abstract]
Retirement benefit obligation
Equity [Abstract]
Quotaholders’ and stockholders’ equity
Share-based Payment Arrangement [Abstract]
Share-based compensation
Related Party Transactions [Abstract]
Related parties
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies
Subsequent Events [Abstract]
Subsequent events
Basis of presentation
Principles of consolidation
Use of estimates
Cash and cash equivalents
Net loss and comprehensive loss
Net loss
Foreign currency translation
Emerging growth company status
Fair value measurements
Segment information
Tax credit on investments in research and development
Share-based compensation
Representative warrants
Property and equipment
Impairment of long-lived assets
Deferred offering costs
Recently issued accounting pronouncements
Schedule of cash and cash equivalents
Schedule of deferred offering costs
Schedule of effective income tax rate reconciliation
Schedule of deferred tax assets
Schedule of tax loss carryforwards expire
Schedule of prepaid expenses and other current assets
Schedule of property and equipment net
Schedule of other non-current assets
schedule of equity method investment and ownership percentage
schedule of outstanding stock options
schedule of share based compensation expenses
schedule of third party and general and administrative expenses
schedule of accounts payable to related parties
schedule of accrued expenses to related parties
schedule of company obligations by contractual maturity
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Subsidiary, Sale of Stock [Line Items]
Conversion of Stock, Shares Issued
Stock Issued During Period, Shares, New Issues
Common Stock, Value, Subscriptions
American depository shares
Common Stock, Shares, Outstanding
Net listing costs
Net Income (Loss) Attributable to Parent
Retained Earnings (Accumulated Deficit)
Cash in bank
Cash in hand & prepaid cards
Total
SEC registration fee
Nasdaq listing fee
FINRA filing fee
Underwriter fees and commissions
Legal fees and expenses
Accounting fees and expenses
Advisory fees
Total
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Share capital increased
Common Stock, Shares Authorized
Common Stock, Capital Shares Reserved for Future Issuance
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Class of warrant or right exercisable percentage of warrants or rights
Class of Warrant or Right, Exercise Price of Warrants or Rights
Useful life
Estimated useful lives
Stock Issued During Period, Value, Other
Deferred offering costs
Income taxes at Italy statutory rate
Permanent differences
Other
Federal Income tax for Genenta INC
Change in valuation allowance
Total provision expense for income taxes
Net operating loss carryforwards
Other
Allowance for corporate equity
Total deferred tax assets
Valuation allowance
Net deferred tax assets
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Total
Deferred Tax Liabilities, Net
Value Added Tax (VAT)
Research and development tax credit
Advances to suppliers- related party
Advances to suppliers
Other current assets
Other prepaids
Total
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plan Disclosure [Line Items]
Percentage of value added tax
Research and development tax credit
Taxes Payable, Current
Research and Development Expense
Due from Related Parties
Legal Fees
Other advance payments for operating services
Computer
Furniture and fixtures
Total property and equipment
Less: accumulated depreciation
Property and equipment, net
Depreciation
Schedule Of Other Non-current Assets
Value Added Tax (VAT)
Total other non-current assets
Other non-current assets related party
Defined contribution plan maximum annual contributions per employee description
Defined contribution plan, maximum annual contributions per employee, percent
Schedule of Equity Method Investments [Table]
Schedule of Equity Method Investments [Line Items]
Total
Ownership percentage
Common stock, voting rights
Nominal amount
Proceeds from capital funding
Financial fees gross
Financial fees net
Corporate capital, percentage
Proceeds from divestiture of businesses
Stock Issued During Period, Value, Stock Options Exercised
Stock Repurchased During Period, Value
Proceeds from Stock Options Exercised
Capital Units, Value
Stock Issued During Period, Value, Conversion of Units
Additional Paid in Capital
Debt Conversion, Converted Instrument, Rate
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance
Weighted average remaining contractual term (years), beginning
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Other than options aggregate intrinsic value granted
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted average remaining contractual term (years), beginning
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
[custom:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageForfeitedPrice]
Other than options aggregate intrinsic value forfeited
Share based compensation arrangement by share based payment award non option equity instruments exercisable
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisablePrice-1]
Other than options aggregate intrinsic value exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance
Other than options aggregate intrinsic value exercisable
Share based compensation arrangement by share based payment award non option equity instruments exercisable
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisablePrice-2]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total
Unrecognized expense
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price
Vesting period
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Stock Issued During Period, Shares, Issued for Services
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum
Weighted average fair value of options granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Fair value of the option as a charge to additional paid-in capital
Weighted Average Number of Shares Outstanding, Basic
Common Stock, Par or Stated Value Per Share
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Line Items]
Total
Total
Total
Total
Research and development expense gross
Deferred Tax Assets, Tax Credit Carryforwards, Research
Shareholder ownership, percentage
Salary and Wage, Officer, Excluding Cost of Good and Service Sold
Annual performance bonus
Salary and Wage, Excluding Cost of Good and Service Sold
Percentage of annual bonus
Interest expense, related party
Accrued Bonuses
Annual fee
Additional fees
Employee Benefits and Share-based Compensation
Employee-related Liabilities
Recurring fees
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold
Due from Employees
Contribution of Property
Other Comprehensive Income (Loss), Tax
Related expense
Accrued liabilities related party
Due to Related Parties
Deferred Compensation Arrangement with Individual, Compensation Expense
Upfront fee
Future option fees
Decreased future option fees
Royalty fee percentage
Repayments of Related Party Debt
Costs and Expenses, Related Party
Payments for merger related costs
Payments for merger related costs gross
Option fee
Interest Expense
Option fee
Sponsored research activities
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total
Payments by period, less than a year
Payments by period, one to three years
Payments by period, four to five years
Payments by period, more than five years
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Production Costs, Period Cost
Potential milestone payments
Debt instrument, periodic payment
Asset Acquisition, Contingent Consideration, Liability
Loss contingency
Payment for license fee
Contingent payments
Debt Related Commitment Fees and Debt Issuance Costs
Cumulative expense
Cumulative manufacturing expense
Technology transfer fee
Production costs percentage
Payment of service costs
Total commitment amount
Total commitment
Payments for Rent
Lease, Cost
Subsequent Event [Table]
Subsequent Event [Line Items]
Milestone payment
Professional Fees
Other non-current assets related party.
American depository shares.
Accounts payable related party.
Accrued liabilities related party.
Retirement benefit obligation.
Net listing costs.
Share capital increased.
Corporate Capital [Member]
Adjustment to additional paid in capital increase net of issuance costs.
Capital increase from IPO net of issuance costs.
Corporate capital adjustment from Srl to SPA share.
Capital increase related to SPA share.
Capital increase from IPO net issuance costs share.
Equity Incentive Plan 2021 - 2025 [Member]
Emerging growth company status [PolicyTextBlock]
Increase decrease in accounts payable related party.
Increase decrease in accrued liabilities related party.
Schedule of deferred offering costs [Table Text Block]
Other than options aggregate intrinsic value exercisable.
Other than options aggregate intrinsic value granted.
Other than options aggregate intrinsic value forfeited.
American Depositary Shares [Member]
Awards and subsidies.
Finance income expenses.
Contingent payments.
Deferred accounting fees and expenses.
Consultants And Other Services [Member]
Deferred legal fees and expenses.
Cumulative expense.
Deferred underwriter fees and commissions.
Materials And Supplies [Member]
Compensation [Member]
Travel And Entertainment [Member]
Other [Member]
Deferred finra filing fee.
Royalty fee percentage.
Deferred nasdaq listing fee.
Securities and exchange commission registration fee.
Accounting Legal and Other Professional [Member]
Communication and IT Related [Member]
Facility and Insurance Related [Member]
Consultants and Other Third Parties [Member]
Amendment Four [Member]
Amendment Five [Member]
Amendment Six [Member]
Research And Development Expense Related Party [Member]
Equipment And Furniture [Member]
Electronic Office Equipment [Member]
Deferred advisory fees.
Third Parties [Member]
Related Parties [Member]
Potential milestone.
AGC Biologics Agreement [Member]
Technology transfer fee.
AGC Agreement [Member]
Research and development expense decrease.
San Raffle Hospital [Member]
Defined contribution plan maximum annual contributions per employee description.
Second option exercised.
Corporate capital adjustment from srl to spa.
Capital increase related to spa.
Schedule of accounts payable to related parties [Table Text Block]
GMP Batch [Member]
San Raffaele Hospital [Member]
Production costs percentage.
XDG Biomed LLC [Member]
Schedule of accrued expense to related parties [Table Text Block]
Service Agreement [Member]
Pierluigi Paracchi [Member]
Richard Slansky [Member]
Accrued option fee.
Spafid SPA [Member]
Fidim Srl [Member]
Biotechnologies Agreement [Member]
Payment of service costs.
Biogazelle Agreement [Member]
Quota A [Member]
Quota B [Member]
Quota C [Member]
Quota D [Member]
Research and development expense gross.
Quota E [Member]
Annual performance bonus.
Percentage of annual bonus.
Annual fee.
Naldini [Member]
Additional fees.
Gentner [Member]
Tax Credit On Investments In Research And Development [Policy Text Block]
General And Administrative Disclosure [Text Block]
Roth Capital [Member]
Other Non Current Assets [Text Block]
OSR Operating Leases And Office Rent [Member]
AGC Manufacturing [Member]
Research and development tax credit.
Deferred tax assets allowance for corporate equity.
LVV Batch [Member]
Plasmid Batch [Member]
Lympho hematopoietic [Member]
Solid Cancer [Member]
No Expiration Date [Member]
Related Milestone One [Member]
Related Milestone Two [Member]
No Expiration Date - DL 98/2011 [Member]
Schedule Of Tax Loss Carryforwards Expire [Table Text Block]
Share based compensation arrangement by share based payment award non option equity instruments exercisable.
Percentage of value added tax.
Share based compensation arrangements by share based payment award options exercises in period weighted average forfeited price.
Representative Warrants Policy [Text Block]
Lock Up Agreements [Policy Text Block]
Share based compensation arrangement by share based payment award non option equity instruments weighted average exercisable price.
OSR [Member]
Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding weighted average remaining contractual term vested and exercised.
Recurring fees.
Schedule of equity method investment ownership percentage [Table Text Block]
Upfront fee.
License Agreement Amendment [Member]
Incurred and expensed
Nominal amount
License Agreement Amendment One [Member]
Proceeds from capital funding
License Agreement Amendment Two [Member]
License Agreement Amendment Three [Member]
Payments for merger related costs gross
Financial fees gross
Financial fees net
License Agreement Amendment Five [Member]
Research Funding Agreement [Member]
Future option fees
First Indication [Member]
Second Indication [Member]
Third Indication [Member]
Decreased future option fees
Payment for option fee.
First Solid Cancer Indication [Member]
Second Solid Cancer Indication [Member]
Increase in payment for exercise option fee.
Contractual obligation due in one to third year
Other prepaid expense current related party.
Corporate capital value
Other prepaid expense current related party
Other advance payments for operating services
Class of warrant or right issued
Class of warrant or right exercisable percentage of warrants or rights
Sponsor Research Agreement [Member]
Sponsor research activities
Payments by period, less than a year
Shareholder ownership, percentage
Corporate capital, percentage
Second Option [Member]
First Option [Member]
Income tax reconciliation income tax expense benefit at federal income tax rate.
Amendment Seven [Member]
Payment for commitment.
Employment Agreement [Member]
Prepaid expenses and other current assets - related party.
Prepaid offering costs.
Non-cash financing activities: deferred offering costs accrued at year end.
Milestone payment.
Net Loss and Comprehensive Loss [Policy Text Block]
OSR-SanRaffaeleHospital [Member]
Non-cash financing activities: accrued IPO offering costs.
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Assets, Current
Assets, Noncurrent
Assets [Default Label]
Liabilities, Current
Liabilities, Noncurrent
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Shares, Outstanding
Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Noncurrent Assets
Increase (Decrease) in Accounts Payable
Increase decrease in accounts payable related party
Increase (Decrease) in Accrued Liabilities
Increase decrease in accrued liabilities related party
Increase (Decrease) in Other Current Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Payments of Stock Issuance Costs
PaymentsForPrepaidOfferingCosts
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Research, Development, and Computer Software Disclosure [Text Block]
General And Administrative Disclosure [Text Block]
Other Current Assets [Text Block]
Property, Plant and Equipment Disclosure [Text Block]
OtherNonCurrentAssetsTextBlock
Retirement Benefits [Text Block]
Stockholders' Equity Note Disclosure [Text Block]
Share-based Payment Arrangement [Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Earnings Per Share, Policy [Policy Text Block]
Share-based Payment Arrangement, Forfeiture [Policy Text Block]
Deferred Tax Assets, Other
Deferred Tax Assets, Valuation Allowance
Operating Loss Carryforwards
Prepaid Expense, Current
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Value Added Tax Receivable, Noncurrent
Equity Method Investments
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTermVestedAndExercised
Share based compensation arrangement by share based payment award non option equity instruments exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisablePrice
Other than options aggregate intrinsic value exercisable
Share-based Payment Arrangement, Expense
Accounts Payable, Related Parties, Current
Increase in payment for exercise option fee
Contractual Obligation